MAY 24, 2019 2:36 PM PDT

New Therapeutic Target for Depression

WRITTEN BY: Nouran Amin

In a study published in the Journal of Psychopharmacology, a new drug target for the treatment of depression has been identified by researchers at the Department of Human Physiology of the UMA Faculty of Medicine.

The study stemmed from the research group, “Neurochemistry of the Transmission in the Central Nervous System”, co-directed by Professor Zaida Díaz-Cabiale, where they identified ‘GAL (1-15)’--part of the neuropeptide molecule called Galanin.

Galanin is central to the common symptom of depression—anhedonia, the loss of pleasure in daily activities.

“We have verified through different experiments how animals modify their response to high-reinforcement appetitive stimuli, such as saccharine or sexual attraction, after the administration of the Galanin fragment”, explains researcher Carmelo Millón, one of the authors of this study. “The understanding of these mechanisms opens the way for endless therapeutic strategies, hence its importance.”

Researchers from Karolinska Institute in Sweden also collaborated on the study and examined the molecular interactions of brain reinforcement system. They observed that the brains' ability to support positive behavior was inhibited by the Galanin fragment which reaffirmed the initial findings.

Most therapeutics for depression are SSRIs (selective serotonin reuptake inhibitors)—such drugs can take up to two weeks to start showing signs of treatment with a further 30 percent of patients who receive the medication are resistant to the treatment.

Learn more about the future of depression treatments:

Source: Drug Target Review

 

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JAN 14, 2020
Drug Discovery & Development
JAN 14, 2020
Can Silica Treat Obesity and Diabetes?
Silica particles, specifically ‘mesoporous silica particles (MSPs)’ are engineered molecular traps that may provide a breakthrough treatment op...
FEB 25, 2020
Drug Discovery & Development
FEB 25, 2020
Treating stroke with low dose of clot-busting drug
A study concludes that a low-dose of the clot-busting drug—tenecteplase—may be beneficial for eligible stroke patients that do not need an inte...
FEB 27, 2020
Drug Discovery & Development
FEB 27, 2020
New Drug Shows Promise in Treating Chronic Cough
Between 4% and 10% of adults around the world have an unexplainable chronic cough that has lasted for over 8 weeks. Although no treatments are currently av...
MAR 08, 2020
Microbiology
MAR 08, 2020
A Supercomputer Aids in the Hunt for COVID-19 Therapeutics
It is seeming more likely that COVID-19, caused by the coronavirus SARS-CoV-2, will impact many people....
MAR 16, 2020
Drug Discovery & Development
MAR 16, 2020
Critical Interleukin Leads to Drug Discovery
The immune molecule interleukin-2 (IL-2) is a growth factor that stimulates the immune system to produce T-cells. Their powerful effects have encouraged re...
MAR 24, 2020
Drug Discovery & Development
MAR 24, 2020
How Will the Coronavirus Change Drug Development?
Cataclysmic bombshells to society- be they actual bombshells by means of war, or metaphorical ones by natural catastrophe or financial collapse, tend to la...
Loading Comments...